Search

everythinglearnresearchcommunity

for

Search:↓

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

The document concludes that various drugs can manage symptoms and metabolic issues in women with PCOS.

The enzymes 5α-reductase and 3α/β-hydroxysteroid oxidoreductase help create brain-active substances from progesterone and testosterone, which could be used for treatment, but more research is needed to ensure their safety and effectiveness.

Allethrin caused harmful effects and organ damage in rats, worsening with higher doses and longer exposure.

Treating excessive hair in women requires a holistic approach, including medical, aesthetic, and emotional support.

The document concludes that low-dose oral contraceptives and hormonal therapies can manage perimenopause symptoms and reduce some health risks, but lifestyle changes and disease screening are also important.

Hormones affect skin aging and fat distribution, and treatments can help, but only minoxidil is proven for female hair loss.

The document concludes that various cosmetic and drug treatments are available for hirsutism, and some new drugs show promise.

The document concludes that treatments for female hair loss and excessive hair growth are temporary and not well-studied.

Skin diseases linked to insulin resistance should be managed to prevent diabetes and reduce heart disease risk.

The conclusion is that while oral contraceptive pills are effective for PCOS-related high androgen levels, new treatments with fewer side effects are needed.

Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.

New treatments for excessive hair growth in women include insulin modulators and enzyme inhibitors.

Alternative treatments show promise for hair growth beyond traditional methods.

Excessive hair growth in women can be harmless or signal serious health issues, and treatment often includes medication and hair removal, with noticeable results after 3-6 months.

Cyproterone acetate with ethinyl estradiol is effective for treating skin symptoms related to high androgen levels, like in PCOS.

New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.

Women with PCOS have a higher risk of heart disease due to factors like insulin resistance and obesity.

Drugs for hormone-related conditions might help treat mental disorders but could have serious side effects.

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.

Testosterone therapy may improve mood, well-being, and sexual function in premenopausal women, but more research is needed on its long-term safety and effectiveness.

Spironolactone is effective for acne, hidradenitis suppurativa, female hair loss, and hirsutism but is underused in dermatology.

Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.

The conclusion is that managing cholesterol is important for women, especially during pregnancy, breastfeeding, and with PCOS, and involves regular screening and careful treatment choices.

PGF_2α receptors in human eyelids are found in specific parts of hair follicles, explaining eyelash changes with glaucoma treatment.

The document concludes that managing PCOS involves treating symptoms and reducing long-term metabolic risks, with lifestyle changes being important.

Using rodents for research shows that health problems in the womb can cause diseases later in life.

Women with PCOS are at high risk of glucose metabolism issues and heart diseases, especially if overweight, highlighting the need for early intervention.

Hormone therapy may increase migraines in transgender women and decrease them in transgender men; more research is needed on migraine management in transgender individuals.

The use of Diane-35 and its generics significantly decreased in the Netherlands.